Non-small cell lung cancer Receiving Chemotherapy Non-small cell lung cancer Chemotherapy, Platinum-based Dosage Intensity Progression-Free Survival Retrospective Cohort Studies Kaplan-Meier Estimate Cox Proportional Hazards Models Thailand
Conditions
Interventions
NSCLC who receive platinum-based chemotherapy as a first-line treatment.
Treatment
Overall NSCLC
Sponsors
Department of Medicine, Maharat Nakhon Ratchasima Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients of both sexes over 18 years old who were diagnosed with advanced-stage non-small cell lung cancer were included. As the first-line treatment, platinum-containing chemotherapy was required for all patients. ECOG Performance must be between 0 and 2.
Exclusion criteria
Exclusion criteria: Patients having previous malignancies in the preceding five years, excluding basal cell carcinoma and other localized skin cancers, were excluded from the study. Other exclusion criteria comprised patients with platinum-containing chemotherapy during the preceding 12 months or those with uncontrolled brain metastases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival SoC CT schedule, Death RECIST Version 1.1 | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival Death Death status, Date of Death or Date of Last Follow up in Loss F/U case,Overall response rate SoC CT schedule RECIST Version 1.1,Interested Adverse Event SoC visit schedule CTCAE v. 5 | — |
Countries
Thailand
Contacts
Public ContactJirawat Thanestada
Maharat Nakhon Ratchasima hospital
Outcome results
None listed